Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder

Phase 1

• Conditions: Major Depressive Disorder; Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

• Registration Number: EUCTR2008-001876-67-Outside-EU/EEA
• Lead Sponsor: Pfizer Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-07-27
• Last Update Posted: 8 August 2016

Recruitment & Eligibility

• Status: A
• Sex: All
• Target Recruitment: 283

Inclusion Criteria

1 - Completed study B2061032 and who in the investigator’s opinion, would benefit from long term treatment with DVS SR

2 - Willingness and ability to comply with scheduled visits, treatment plan, and procedures

Are the trial subjects under 18? yes
Number of subjects for this age range: 283
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1 - Requires precaution against suicide

2 - Not generally healthy medical condition

3 - Poor compliance with study drug or study procedures during participation in study B2061032

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified